|Table of Contents|

Theoretical basis and research progress of anti-angiogenesis combined with immune checkpoint inhibitors in the treatment of advanced renal carcinoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 05
Page:
979-984
Research Field:
Publishing date:

Info

Title:
Theoretical basis and research progress of anti-angiogenesis combined with immune checkpoint inhibitors in the treatment of advanced renal carcinoma
Author(s):
GUO Shengyue; WANG Yan
Department of Oncology,Harbin Medical University Cancer Hospital，Heilongjiang Harbin 150081,China.
Keywords:
malignant kidney neoplasms; antiangiogenic therapy; immune checkpoint inhibitors
PACS:
R737.11
DOI:
10.3969/j.issn.1672-4992.2023.05.038
Abstract:
In recent years,anti-angiogenesis combined with immune checkpoint inhibitors in the treatment of malignant tumors has become a research hotspot.The theoretical basis of these studies is that the interaction between the immune system and the angiogenic system increases anti-tumor activity.For example,Food and Drug Administration （FDA） has approved avelumab in combination with axitinib for first-line treatment of advanced kidney cancer.Although anti-angiogenesis combined with immune checkpoint inhibitors has been shown to be effective in the treatment of advanced renal cancer,they have also exacerbated treatment-related adverse reactions.Although most patients experienced irAE during the interval of immune checkpoint inhibitors' treatment,it was found that the combination therapy did not aggravate irAEs,but was associated with the toxic effects of antiangiogenic drugs.Therefore,the purpose of this article is to summarize the theoretical basis and research progress of advanced renal carcinoma with anti-angiogenesis combined with immune checkpoint inhibitors.

References:

［1］ZHOU X,HOU W,GAO L,et al.Synergies of antiangiogenic therapy and immune checkpoint blockade in renal cell carcinoma: From theoretical background to clinical reality［J/OL］.Front-Oncol,2020,10:1321.［2020-07-09］.https://pubmed.ncbi.nlm.nih.gov/32850419/.doi:10.3389/fonc.2020.01321.
［2］JIANG W,HUANG Y,AN Y,et al.Remodeling tumor vasculature to enhance delivery of intermediate-sized nanoparticles［J］.ACS Nano,2015,9(9): 8689-8696.
［3］HUANG Y,GOEL S,DUDA DG,et al.Vascular normalization as an emerging strategy to enhance cancer immunotherapy［J］.Cancer Research,2013,73(10): 2943-2948.
［4］QIAN B,POLLARD JW.Macrophage diversity enhances tumor progression and metastasis［J］.Cell,2010,141(1): 39-51.
［5］TAYLOR CT,COLGAN SP.Regulation of immunity and inflammation by hypoxia in immunological niches［J］.Nat Rev Immunol,2017,17(12): 774-785.
［6］ZHOU Y,MIAO J,WU H,et al.PD-1 and PD-L1 expression in 132 recurrent nasopharyngeal carcinoma: The correlation with anemia and outcomes［J］.Oncotarget,2017,8(31): 51210-51223.
［7］HUANG Y,STYLIANOPOULOS T,DUDA DG,et al.Benefits of vascular normalization are dose and time dependent-letter［J］.Cancer Research,2013,73(23): 7144-7146.
［8］CURRAN MA,MONTALVO WB,YAGITA H,et al.PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors［J］.Proc Natl Acad Sci USA,2010,107(9): 4275-4280.
［9］D' ANIELLO C,BERRETTA M,CAVALIERE C,et al.Biomarkers of prognosis and efficacy of anti-angiogenic therapy in metastatic clear cell renal cancer［J/OL］.Front Oncol,2019,9:1400［2019-12-11］.https://pubmed.ncbi.nlm.nih.gov/31921657/.doi:10.3389/fonc.2019.01400.
［10］ROSKOSKI JR R.Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update［J/OL］.Pharmacol-Res,2021,175:106037［2022-01-01］.https://doi.org/10.1016/j.phrs.2021.106037.
［11］PAL SK,MCDERMOTT DF,ATKINS MB,et al.Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma［J］.BJU Int,2020,126(1): 73-82.
［12］RINI BI,POWLES T,ATKINS MB,et al.Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): A multicentre,open-label,phase 3,randomised controlled trial［J］.Lancet,2019,393(10189): 2404-2415.
［13］ATKINS MB,RINI BI,MOTZER RJ,et al.Patient-reported outcomes from the phase III randomized immotion151 trial: Atezolizumab+bevacizumab versus sunitinib in treatment-naive metastatic renal cell carcinoma［J］.Clin Cancer Res,2020,26(11):2506-2514.
［14］MOTZER RJ,POWLES T,ATKINS MB,et al.Final overall survival and molecular analysis in immotion151,a phase 3 trial comparing atezolizumab plus bevacizumab vs sunitinib in patients with previously untreated metastatic renal cell carcinoma［J］.JAMA Oncol,2022,8(2):275-280.
［15］RINI BI,MOTZER RJ,POWLES T,et al.Atezolizumab plus bevacizumab versus sunitinib for patients with untreated metastatic renal cell carcinoma and sarcomatoid features: A prespecified subgroup analysis of the immotion151 clinical trial［J］.Eur Urol,2020,79 (5):659-662.
［16］SUAREZ C,CHOUEIRI TK,MCDERMOTT DF,et al.Safety and tolerability of atezolizumab (atezo) plus bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC): Pooled analysis of IMmotion150 and IMmotion151［J/OL］.Annals of Oncology,2018,29:viii308［2018-10-29］.https://sci-hub.ren/10.1093/annonc/mdy283.082.doi: 10.1093/annonc/mdy.283.082.
［17］MCGREGOR BA,MCKAY RR,BRAUN DA,et al.Results of a multicenter phase II study of atezolizumab and bevacizumab for patients with metastatic renal cell carcinoma with variant histology and/or sarcomatoid features［J］.J Clin Oncol,2020,38(1): 63-70.
［18］DUDEK AZ,LIU LC,GUPTA S,et al.Phase Ib/II clinical trial of pembrolizumab with bevacizumab for metastatic renal cell carcinoma: BTCRC-GU14-003［J］.J Clin Oncol,2020,38(11):1138-1145.
［19］CHOUEIRI TK,LARKIN J,OYA M,et al.Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): An open-label,dose-finding and dose-expansion,phase 1b trial［J］.Lancet Oncol,2018,19(4): 451-460.
［20］MOTZER R.J,PENKOV K,HAANEN J,et al.Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma［J］.N Engl J Med,2019,380(12): 1103-1115.
［21］CHOUEIRI TK,MOTZER RJ,RNI BI,et al.Updated efficacy results from the JAVELIN Renal 101 trial: First-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma［J］.Ann Oncol,2020,31(8):1030-1039.
［22］ ESCUDIER B,PORTA C,SCHMIDINGER M,et al.Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis,treatment and follow-up［J］.Ann Oncol,2019,30(5): 706-720.
［23］CHOUEIRI TK,LARKIN J,PAL S,et al.Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: Post hoc analysis of a randomized clinical trial［published correction appears in ESMO Open.2021 Aug;6(4):100177］［J/OL］.ESMO Open,2021,6(3):100101［2021-08-01］.http://sci-hub.se/10.1016/j.esmoop.2021.100177.doi:10.1016/j.esmoop.2021.100101.
［24］DI NUNNO,V SANTONI,M MASSARI,et al.axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: A non-randomised,open-label,dose-finding,and dose-expansion phase 1b trial［J/OL］.Lancet Oncol,2018,19:405-415.［2018-08-01］.https://pubmed.ncbi.nlm.nih.gov/29709313/.doi: 10.1016/j.eururo.2018.04.015.
［25］ATKINS MB,PLIMACK ER,PUZANOV I,et al.Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: A non-randomised,open-label,dose-finding,and dose-expansion phase 1b trial［J］.Lancet Oncol,2018,19(3): 405-415.
［26］RINI BI,PLIMACK ER,STUS V,et al.Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma［J］.N Engl J Med,2019,380(12): 1116-1127.
［27］ESCUDIER B.Combination therapy as first-line treatment in metastatic renal-cell carcinoma［J］.N Engl J Med,2019,380(12): 1176-1178.
［28］NADAL R,MORTAZAVI A,STEIN MN,et al.Results of phase I plus expansion cohorts of cabozantinib (Cabo) plus nivolumab (Nivo) and CaboNivo plus ipilimumab (Ipi) in patients (pts) with with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies［J/OL］.Journal of Clinical Oncology,2018,36 (6_suppl): 515［2018-02-20］.https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.6_suppl.515.
［29］CHOUEIRI TK,POWLES T,BUROTTO M,et al.Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma［J］.N Engl J Med,2021,384(9):829-841.
［30］MOTZER RJ,POWLES T,BUROTTO M,et al.Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): Long-term follow-up results from an open-label,randomised,phase 3 triall［J］.Lancet Oncol,2022,23(7):888-898.
［31］PAL SK,MCGREGOR B,SUAREZ C,et al.Cabozantinib in combination with atezolizumab for advanced renal cell carcinoma: Results from the COSMIC-021 study［J］.J Clin Oncol,2021,39(33):3725-3736.
［32］ALBIGES L,BARTHELEMY P,GROSS-GOUPIL M,et al.TiNivo: Safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma［J］.Ann Oncol,2020,32 (1): 97-102.
［33］AMIN A,PLIMACK ER,ERNSTOFF MS,et al.Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study［J/OL］.J Immunother Cancer,2019,7(1):73［2019-03-14］.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416882/.doi:10.1186/s40425-019-0559-0563.
［34］CHOWDHURY S,MCDERMOTT DF,VOSS MH,et al.A phase I/II study to assess the safety and efficacy of pazopanib (PAZ) and pembrolizumab (PEM) in patients (pts) with advanced renal cell carcinoma (aRCC)［J/OL］.Journal of Clinical Oncology,2017,35(15_suppl): 4506.［2017-05-20］.https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.4506.
［35］GAO L,YANG X,YI C,et al.Adverse events of concurrent immune checkpoint inhibitors and antiangiogenic agents: A systematic review［J/OL］.Front Pharmacol,2019,10:1173［2019-10-17］.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6812341/.doi：10.3389/fphar.2019.01173.
［36］QIN S,LI A,YI M,et al.Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy［J/OL］.J Hematol Oncol,2019,10:1173［2019-03-12］.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417086/.doi:10.3389/fphar.2019.01173.
［37］BRAHMER JR,LACCHETTI C,THOMPSON JA.Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline summary［J］.J Oncol Pract,2018,14(4): 247-249.
［38］HOEFSMIT EP,ROZEMAN EA,HAANEN J,et al.Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse-events［J/OL］.ESMO-Open,2019,4(4):e000472［2019-07-21］.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6677983.doi:10.1136/esmoopen-2018-000472.
［39］FUKUMURA D,KLOEPPER J,AMOOZGAR Z,et al.Enhancing cancer immunotherapy using antiangiogenics: Opportunities and challenges［J］.Nat Rev Clin Oncol,2018,15(5): 325-340.

Memo

Memo:
-
Last Update: 2023-01-31